Table 1.
Baseline characteristics
| Good-risk, imatinib group (n=46) | Good-risk, no imatinib group (n=44) | Poor-risk group (n=70) | ||
|---|---|---|---|---|
| Female | 17 (37%) | 16 (36%) | 26 (37%) | |
| Male | 29 (63%) | 28 (64%) | 44 (63%) | |
| Age at diagnosis | ||||
| <10 years | 28 (61%) | 28 (64%) | 29 (41%) | |
| ≥10 years | 18 (39%) | 16 (36%) | 41 (59%) | |
| White blood cell count (cells per μL) | ||||
| Data not available | 0 | 2 | 1 | |
| <50 | 29 (63%) | 25 (60%) | 20 (29%) | |
| 50–100 | 6 (13%) | 6 (14%) | 14 (20%) | |
| >100 | 11 (24%) | 11 (26%) | 35 (51%) | |
| Immunophenotype | ||||
| Data not available | 0 | 0 | 1 | |
| Common | 21 (46%) | 19 (43%) | 41 (59%) | |
| Pre-B | 20 (43%) | 19 (43%) | 19 (28%) | |
| Pro-B | 1 (2%) | 0 (0%) | 3 (4%) | |
| Other B cell precursor | 4 (9%) | 5 (11%) | 5 (7%) | |
| T-cell lineage | 0 (0%) | 1 (2%) | 1 (1%) | |
| CNS involvement | ||||
| Not assessable | 1 (2%) | 2 (5%) | 4 (6%) | |
| Yes | 4 (9%) | 4 (9%) | 4 (6%) | |
| No | 41 (89%) | 38 (86%) | 62 (89%) | |
| t (9;22)(q34;q11) | ||||
| Fluorescence in-situ hybridisation only | 14 (30%) | 18 (41%) | 23 (33%) | |
| Real-time PCR only | 10 (22%) | 11 (25%) | 17 (24%) | |
| Both | 22 (48%) | 15 (34%) | 30 (43%) | |
| If real-time PCR, transcript detected | ||||
| Data not available | 7 | 6 | 7 | |
| p190 | 23 (92%) | 18 (90%) | 31 (78%) | |
| p210 | 2 (8%) | 2 (10%) | 9 (23%) | |
| Early response* | ||||
| Yes (peripheral blood) | 23 (50%) | 22 (50%) | 1 (1%) | |
| No (peripheral blood) | 0 (0%) | 0 (0%) | 39 (56%) | |
| Yes (bone marrow) | 23 (50%) | 22 (50%) | 3 (4%) | |
| No (bone marrow) | 0 (0%) | 0 (0%) | 27 (39%) | |
| Minimal residual disease at end of induction† | ||||
| Data not available | 16 | 21 | 23 | |
| <5×10−4 | 11 (37%) | 15 (65%) | 2 (4%) | |
| ≥5×10−4 | 19 (63%) | 8 (35%) | 45 (96%) | |
*
Early response was assessed in bone marrow in COALL, FRALLE, MRC, and NOPHO, and in peripheral blood in the other groups.
†
Hong-Kong and PINDA did not contribute data.